1 はじめに 23
1.1 調査目的 23
1.2 市場の定義 23
1.3 調査範囲 24
1.3.1 考慮したセグメント 24
1.3.2 含むものと含まないもの 25
1.3.3 考慮した年数 25
1.3.4 通貨
1.4 利害関係者 26
2 調査方法 27
2.1 調査データ 27
2.1.1 二次データ 27
2.1.1.1 二次調査の主な情報源 28
2.1.1.2 二次資料からの主要データ 29
2.1.2 一次データ 29
2.1.2.1 一次調査の目的 30
2.1.2.2 一次資料からの主要データ 30
2.1.2.3 主要な業界洞察 31
2.1.2.4 一次データの内訳 31
2.2 市場規模の推定 33
2.2.1 供給サイド分析（収益シェア分析） 33
2.2.2 企業プレゼンテーションとプライマリーインタビュー 34
2.2.3 トップダウンアプローチ：サプライサイド分析 36
2.3 データの三角測量 39
2.4 市場シェアの推定 40
2.5 調査の前提 40
2.6 調査の限界 41
2.7 リスク評価 41
3 エグゼクティブ・サマリー
4 プレミアムインサイト
4.1 歯科軟組織再生市場の概要 45
4.2 アジア太平洋地域：歯科軟組織再生市場、
製品タイプ別、国別（2023年） 46
4.3 歯科軟組織再生市場：地域ミックス 47
4.4 歯科軟組織再生市場：地理的成長機会 47
4.5 歯科軟組織再生市場：新興市場vs. 先進国市場 48
5 市場の概要 49
5.1 はじめに 49
5.2 市場ダイナミクス 49
5.2.1 推進要因 50
5.2.1.1 歯周病有病率の上昇 50
5.2.1.2 審美歯科に対する需要の高まり 50
5.2.1.3 生分解性バイオマテリアルの人気上昇 51
5.2.1.4 再生技術の進歩 51
5.2.2 阻害要因 52
5.2.2.1 歯科保険償還の不十分さと歯科サービスの高額さ 52
5.2.2.2 訓練を受けた歯科医師の不足 52
5.2.3 機会 53
5.2.3.1 歯科サービス組織の導入と歯科診療所の統合 53
5.2.3.2 新興国における成長機会 53
5.2.3.3 新興国におけるデンタルツーリズムの人気の高まり 53
5.2.4 課題 54
5.2.4.1 価格圧力と市場競争の激化 54
5.2.4.2 厳しい規制環境 54
5.3 業界動向 55
5.3.1 デジタル歯科医療の進歩 55
5.3.2 低侵襲歯科処置の増加 55
5.4 バリューチェーン分析 55
5.5 技術分析 57
5.5.1 主要技術 57
5.5.1.1 3Dバイオプリンティング 57
5.5.2 補足技術 57
5.5.2.1 レーザー支援技術 57
5.5.3 隣接技術 58
5.5.3.1 先端バイオマテリアル 58
5.6 ポーターの5つの力分析 58
5.6.1 新規参入の脅威 60
5.6.2 代替品の脅威 60
5.6.3 供給者の交渉力 60
5.6.4 買い手の交渉力 60
5.6.5 競合の激しさ 61
5.7 主要ステークホルダーと購買基準 61
5.7.1 購入プロセスにおける主要ステークホルダー 61
5.7.2 主要な購買基準 62
5.8 規制情勢分析 62
5.8.1 規制機関、政府機関、その他の組織 63
5.8.2 規制の枠組み 65
5.8.2.1 北米 65
5.8.2.1.1 米国 65
5.8.2.2 欧州 66
5.8.2.3 アジア太平洋地域 67
5.8.2.3.1 インド 67
5.8.2.3.2 中国 67
5.8.2.3.3 日本 67
5.9 特許分析 67
5.9.1 主な特許取得状況 69
5.10 貿易分析 70
5.10.1 HSコード300640の輸入データ 70
5.10.2 HSコード300640の輸出データ 71
5.11 価格分析 71
5.11.1 歯科用軟組織再生製品の主要メーカー別希望小売価格 72
5.11.2 歯科用軟組織再生製品の地域別希望小売価格 73
5.12 主要会議・イベント（2024-2025年） 74
5.13 未充足ニーズ／エンドユーザーの期待 75
5.14 隣接市場分析 76
5.15 エコシステム分析 76
5.16 ケーススタディ分析 78
5.17 サプライチェーン分析 80
5.18 顧客のビジネスに影響を与えるトレンド／混乱 81
5.19 投資と資金調達のシナリオ 82
5.20 保険償還シナリオ分析 82
5.21 歯科軟組織再生市場におけるAI/GEN AIの影響 83
5.22 主要地域別歯肉疾患の有病率（2023年） 84
5.23 主要地域別の総手術件数（2023年） 84
6 歯科軟組織再生市場：製品タイプ別 85
6.1 はじめに
6.1.1 コラーゲンベースのメンブレン 86
6.1.1.1 歯科組織再生を強化する可能性が市場を牽引 86
6.1.2 自家移植 87
6.1.2.1 高い適合性と感染リスクの低減が市場を牽引 87
6.1.3 合成生体材料 88
6.1.3.1 生体材料の技術的進歩が市場の成長を促進 88
6.1.4 その他の製品 90
7 歯科軟組織再生市場：用途別 92
7.1 はじめに 93
7.1.1 インプラント分野 93
7.1.1.1 インプラントによる軟組織再生へのニーズの高まりが市場を牽引 93
7.1.2 歯周病学 94
7.1.2.1 歯周病有病率の増加が市場成長を促進 94
7.1.3 その他の用途 95
8 歯科軟組織再生市場：エンドユーザー別 97
8.1 導入 98
8.2 歯科病院 98
8.2.1 口腔の健康に対する意識の高まりが市場を後押し 98
8.3 DSOと独立クリニック 99
8.3.1 歯科治療の進歩が需要を促進 99
8.4 学術・研究機関 101
8.4.1 先進的な歯科ソリューションの開発が市場成長を促進 101
9 歯科軟組織再生市場：地域別 103
9.1 はじめに 104
9.2 北米 105
9.2.1 北米のマクロ経済見通し 105
9.2.2 米国 108
9.2.2.1 北米の歯科軟組織再生市場は米国が支配的 108
9.2.3 カナダ 110
9.2.3.1 厳しい規制遵守がカナダ市場の成長を支える 110
9.3 欧州 112
9.3.1 欧州のマクロ経済見通し 112
9.3.2 ドイツ 115
9.3.2.1 欧州における歯科軟組織再生市場はドイツが支配的 115
9.3.3 英国 117
9.3.3.1 老年患者の増加が市場を牽引 117
9.3.4 フランス 119
9.3.4.1 整備された医療制度が市場を牽引 119
9.3.5 スペイン 120
9.3.5.1 歯科医療保険を提供する政府の取り組みが市場成長を支える 120
9.3.6 イタリア 122
9.3.6.1 歯科用製品の普及が市場成長を牽引 122
9.3.7 その他のヨーロッパ地域 124
9.4 アジア太平洋地域 125
9.4.1 アジア太平洋地域のマクロ経済見通し 125
9.4.2 日本 128
9.4.2.1 高齢者人口の増加が市場成長を支える 128
9.4.3 中国 130
9.4.3.1 高齢者人口の増加と一人当たり所得の増加が市場成長を支える 130
9.4.4 インド 131
9.4.4.1 歯科医療分野の成長が市場成長を促進 131
9.4.5 オーストラリア 133
9.4.5.1 成長する医療費が市場成長を促進 133
9.4.6 韓国 135
9.4.6.1 整備された医療セクターが市場を牽引 135
9.4.7 その他のアジア太平洋地域 136
9.5 ラテンアメリカ 138
9.5.1 ラテンアメリカのマクロ経済見通し 138
9.5.2 ブラジル 140
9.5.2.1 ラテンアメリカ市場で最大のシェアを占めるブラジル 140
9.5.3 メキシコ 141
9.5.3.1 医療インフラの増加が市場成長を促進 141
9.5.4 アルゼンチン 143
9.5.4.1 歯科技術の進歩が成長を促進 143
9.5.5 その他のラテンアメリカ 145
9.6 中東・アフリカ 146
9.6.1 市場の成長を支えるインフラ整備のための政府の取り組み 146
9.6.2 中東・アフリカのマクロ経済見通し 146
9.7 GCC諸国 148
9.7.1 可処分所得の増加が市場成長を牽引 148
9.7.2 GCC諸国のマクロ経済見通し 148
10 競争環境 150
10.1 概要 150
10.2 主要プレーヤーの戦略／勝利への権利 150
10.2.1 歯科用軟組織再生市場で各社が採用した戦略の概要 151
10.3 収益分析、2019年～2023年 152
10.4 市場シェア分析、2023年 152
10.5 企業評価マトリックス：主要プレイヤー（2023年） 155
10.5.1 スター企業 155
10.5.2 新興リーダー 155
10.5.3 浸透型プレーヤー 155
10.5.4 参加企業 155
10.5.5 企業フットプリント：主要プレーヤー（2023年） 157
10.5.5.1 企業フットプリント 157
10.5.5.2 製品フットプリント 158
10.5.5.3 アプリケーションフットプリント 159
10.5.5.4 エンドユーザーフットプリント 160
10.5.5.5 地域別フットプリント 161
10.6 企業評価マトリクス：新興企業／SM（2023年） 162
10.6.1 進歩的企業 162
10.6.2 対応力のある企業 162
10.6.3 ダイナミックな企業 162
10.6.4 スタートアップ・ブロック 162
10.6.5 競争ベンチマーキング：新興企業／SM、2023年 164
10.7 ブランド／製品の比較 166
10.8 主要企業の研究開発費 167
10.9 企業評価と財務指標 167
10.10 競争シナリオ 168
10.10.1 製品上市 168
10.10.2 取引 169
10.10.3 拡張 171
11 企業プロファイル 172
11.1 主要企業 172
Geistlich Pharma AG (Switzerland)
Dentsply Sirona (US)
Institut Straumann AG (Switzerland)
Zimvie Inc. (US)
Henry Schein Inc. (US)
AbbVie Inc. (US)
Advanced Medical Solutions Group Plc (UK)
Tissue Regenix (UK)
Septodont Holding (France)
Medical Consult Implants GmbH (Germany)
Meccellis (US)
Regedent Ag (Switzerland)
Regenity (US)
Envista (US)
AD Surgical (US)
LifeNet Health (US)
B. & B. Dental S.R.L. (Italy)
Alpha-Bio Tec. Ltd. (Israel)
Lasak S.R.O. (Czechia)
KeystoneDentalGroup (US)
Neoss AG (Switzerland)
Bego GmbH Co. KG (Germany)
Biotech Dental (France)
Samyang Holdings Corporation (South Korea)
and RTI Surgical (US)
12 付録 218
12.1 ディスカッションガイド 218
12.2 Knowledgestore： マーケットサ ンドマーケッツの購読ポータル 222
12.3 カスタマイズオプション 224
12.4 関連レポート 224
12.5 著者の詳細 225
The dental soft-tissue regeneration market has had strong growth due to a number of factors such as the rising incidences of periodontal diseases, increasing awareness of oral health, and growing trend of cosmetic dentistry. Moreover, the initіatіves tо dеvеlop healthcarе infrаstructure іn underdеvеlopеd regions demand morе dental treatments and related products. Additionally, the advancements in regenerative biomaterials has also played a major role in the market's growth.
“By product type, collagen-based segment is expected to have the largest market share in the dental soft-tissue regeneration market.”
Based on the product type, the collagen-based membrane segment is expected to dominate the the dental soft-tissue regeneration market due to several factors. Collagen-based membranes acts as barriers to guide tissue growth, where they support the healing of periodontal defects and implant-based defects. Moreover, these membrnes have the ability to integrate with surrounding tissues and supports the growth of new connective tissue. Furthermore, innovations in regenerative biomaterials further support the growth of this market.
“By application, implantology segment is expected to have the largest market share in the dental soft-tissue regeneration market.”
Based on application, the implantology segment is expected to hold the largest market share in the dental soft-tissue regeneration market due to the growing aging population, increasing awareness of oral health and increasing demand for cosmetic dentistry. Moreover, to promote healing in peri-implant soft tissues, products like collagen membranes, soft tissue grafts, and advanced bioactive materials are increasingly used. Additionally, innovations in soft tissue regenerative solutions, and increasing awareness of dental aesthetics further support the growth of dental soft-tissue regeneration market.
“By region, North American region is expected to have the largest market share in the dental soft-tissue regeneration market.”
North America to register for the highest share of the dental soft-tissue regeneration market during the forecast period due to several factors. The presence of advanced healthcare infrastructure, and high health expenditure rates drive the demand for advanced dental care treatments in this region. Moreover, the significant rise in the geriatric population, which is more prone to periodontal diseases, covers the majority of the treatments required in North America. Favorable government policies, and reimbursement frameworks for dental care treatments, along with a high dental insurance coverage among the patients, supports them toward getting advance dental care treatments. Additonaly, the ongoing research and development in dental technologies and biomaterials, also support this expansion in this region.
A breakdown of the primary participants (supply-side) for the dental soft-tissue regeneration market referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3–25%
• By Designation: C-level–45%, Director Level–35%, and Others–20%
• By Region: North America–27%, Europe–25%, Asia Pacific–30%, Latin America- 8%, Middle East & Africa-10% .
Prominent players in the dental soft-tissue regeneration market are Geistlich Pharma AG (Switzerland), Dentsply Sirona (US), Institut Straumann AG (Switzerland), Zimvie Inc. (US), Henry Schein, Inc. (US), AbbVie Inc. (US), Advanced Medical Solutions Group Plc (UK), Tissue Regenix (UK), Septodont Holding (France), Medical Consult Implants GmbH (Germany), Meccellis (US), Regedent Ag (Switzerland), Regenity (US), Envista (US), AD Surgical (US), LifeNet Health (US), B. & B. Dental S.R.L. (Italy), Alpha-Bio Tec. Ltd. (Israel), Lasak S.R.O. (Czechia), KeystoneDentalGroup (US), Neoss AG (Switzerland), Bego GmbH Co. KG (Germany), Biotech Dental (France), Samyang Holdings Corporation (South Korea), and RTI Surgical (US).
Research Coverage:
The report analyzes the dental soft-tissue regeneration market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, application, end user and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall dental soft-tissue regeneration market. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
Analysis of key drivers (rising prevalence of periodontal diseases, rising awareness and growing demand for cosmetic dentistry, advancements in biomaterials, and advancements in regenerative technology), restraints (inadequate reimbursement and high cost of dental services, and dearth of trained dental practitioners), opportunities (consolidation of dental practices and rising DSO activity, growing focus on emerging economies and rising disposable income levels, and growing dental tourism in emerging countries) and challenges (pricing pressure faced by prominent market players, and stringent regulatory environment).
• Market Penetration: It includes extensive information on products offered by the major players in the global the dental soft-tissue regeneration market. The report includes various segments in product type, application, end user and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global dental soft-tissue regeneration market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by type, application, end user and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the dental soft-tissue regeneration market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global dental soft-tissue regeneration market.
1 INTRODUCTION 23
1.1 STUDY OBJECTIVES 23
1.2 MARKET DEFINITION 23
1.3 STUDY SCOPE 24
1.3.1 SEGMENTS CONSIDERED 24
1.3.2 INCLUSIONS & EXCLUSIONS 25
1.3.3 YEARS CONSIDERED 25
1.3.4 CURRENCY CONSIDERED 26
1.4 STAKEHOLDERS 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
2.1.1 SECONDARY DATA 27
2.1.1.1 Key sources for secondary research 28
2.1.1.2 Key data from secondary sources 29
2.1.2 PRIMARY DATA 29
2.1.2.1 Objectives of primary research 30
2.1.2.2 Key data from primary sources 30
2.1.2.3 Key industry insights 31
2.1.2.4 Breakdown of primaries 31
2.2 MARKET SIZE ESTIMATION 33
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 33
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 34
2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS 36
2.3 DATA TRIANGULATION 39
2.4 MARKET SHARE ESTIMATION 40
2.5 STUDY ASSUMPTIONS 40
2.6 RESEARCH LIMITATIONS 41
2.7 RISK ASSESSMENT 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 45
4.1 DENTAL SOFT-TISSUE REGENERATION MARKET OVERVIEW 45
4.2 ASIA PACIFIC: DENTAL SOFT-TISSUE REGENERATION MARKET,
BY PRODUCT TYPE AND COUNTRY (2023) 46
4.3 DENTAL SOFT-TISSUE REGENERATION MARKET: REGIONAL MIX 47
4.4 DENTAL SOFT-TISSUE REGENERATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 47
4.5 DENTAL SOFT-TISSUE REGENERATION MARKET: EMERGING VS. DEVELOPED MARKETS 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 50
5.2.1.1 Rising prevalence of periodontal diseases 50
5.2.1.2 Growing demand for cosmetic dentistry 50
5.2.1.3 Rising popularity of biodegradable biomaterials 51
5.2.1.4 Advancements in regenerative technologies 51
5.2.2 RESTRAINTS 52
5.2.2.1 Inadequate dental insurance reimbursements and high cost of dental services 52
5.2.2.2 Dearth of trained dental practitioners 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Introduction of dental service organizations and consolidation of dental practices 53
5.2.3.2 Growth opportunities in emerging economies 53
5.2.3.3 Increasing popularity of dental tourism in emerging countries 53
5.2.4 CHALLENGES 54
5.2.4.1 Pricing pressure and increased market competition 54
5.2.4.2 Stringent regulatory environment 54
5.3 INDUSTRY TRENDS 55
5.3.1 ADVANCEMENTS IN DIGITAL DENTISTRY 55
5.3.2 INCREASED NUMBER OF MINIMALLY INVASIVE DENTAL PROCEDURES 55
5.4 VALUE CHAIN ANALYSIS 55
5.5 TECHNOLOGY ANALYSIS 57
5.5.1 KEY TECHNOLOGIES 57
5.5.1.1 3D bioprinting 57
5.5.2 COMPLEMENTARY TECHNOLOGIES 57
5.5.2.1 Laser-assisted technology 57
5.5.3 ADJACENT TECHNOLOGIES 58
5.5.3.1 Advanced biomaterials 58
5.6 PORTER’S FIVE FORCES ANALYSIS 58
5.6.1 THREAT OF NEW ENTRANTS 60
5.6.2 THREAT OF SUBSTITUTES 60
5.6.3 BARGAINING POWER OF SUPPLIERS 60
5.6.4 BARGAINING POWER OF BUYERS 60
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.7 KEY STAKEHOLDERS & BUYING CRITERIA 61
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 61
5.7.2 KEY BUYING CRITERIA 62
5.8 REGULATORY LANDSCAPE ANALYSIS 62
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
5.8.2 REGULATORY FRAMEWORK 65
5.8.2.1 North America 65
5.8.2.1.1 US 65
5.8.2.2 Europe 66
5.8.2.3 Asia Pacific 67
5.8.2.3.1 India 67
5.8.2.3.2 China 67
5.8.2.3.3 Japan 67
5.9 PATENT ANALYSIS 67
5.9.1 KEY PATENTS GRANTED 69
5.10 TRADE ANALYSIS 70
5.10.1 IMPORT DATA FOR HS CODE 300640 70
5.10.2 EXPORT DATA FOR HS CODE 300640 71
5.11 PRICING ANALYSIS 71
5.11.1 INDICATIVE SELLING PRICE OF DENTAL SOFT-TISSUE REGENERATION PRODUCTS, BY KEY PLAYER 72
5.11.2 INDICATIVE SELLING PRICE OF DENTAL SOFT-TISSUE REGENERATION PRODUCTS, BY REGION 73
5.12 KEY CONFERENCES & EVENTS, 2024–2025 74
5.13 UNMET NEEDS/END-USER EXPECTATIONS 75
5.14 ADJACENT MARKET ANALYSIS 76
5.15 ECOSYSTEM ANALYSIS 76
5.16 CASE STUDY ANALYSIS 78
5.17 SUPPLY CHAIN ANALYSIS 80
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
5.19 INVESTMENT & FUNDING SCENARIO 82
5.20 REIMBURSEMENT SCENARIO ANALYSIS 82
5.21 IMPACT OF AI/GEN AI ON DENTAL SOFT-TISSUE REGENERATION MARKET 83
5.22 PREVALENCE OF GINGIVAL DISEASES, BY KEY REGION, 2023 84
5.23 TOTAL NUMBER OF SURGERIES, BY KEY REGION, 2023 84
6 DENTAL SOFT-TISSUE REGENERATION MARKET, BY PRODUCT TYPE 85
6.1 INTRODUCTION 86
6.1.1 COLLAGEN-BASED MEMBRANES 86
6.1.1.1 Potential to enhance dental tissue regeneration to drive market 86
6.1.2 AUTOGRAFTS 87
6.1.2.1 High compatibility and reduced infection risks to drive market 87
6.1.3 SYNTHETIC BIOMATERIALS 88
6.1.3.1 Technological advancements in biomaterials to fuel market growth 88
6.1.4 OTHER PRODUCTS 90
7 DENTAL SOFT-TISSUE REGENERATION MARKET, BY APPLICATION 92
7.1 INTRODUCTION 93
7.1.1 IMPLANTOLOGY 93
7.1.1.1 Growing need for implant-supported soft-tissue regeneration to drive market 93
7.1.2 PERIODONTOLOGY 94
7.1.2.1 Increasing prevalence of periodontal diseases to favor market growth 94
7.1.3 OTHER APPLICATIONS 95
8 DENTAL SOFT-TISSUE REGENERATION MARKET, BY END USER 97
8.1 INTRODUCTION 98
8.2 DENTAL HOSPITALS 98
8.2.1 GROWING AWARENESS OF ORAL HEALTH TO BOOST MARKET 98
8.3 DSOS & INDEPENDENT CLINICS 99
8.3.1 ADVANCEMENTS IN DENTAL CARE TO DRIVE DEMAND 99
8.4 ACADEMIC & RESEARCH INSTITUTES 101
8.4.1 DEVELOPMENT OF ADVANCED DENTAL SOLUTIONS TO BOOST MARKET GROWTH 101
9 DENTAL SOFT-TISSUE REGENERATION MARKET, BY REGION 103
9.1 INTRODUCTION 104
9.2 NORTH AMERICA 105
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 105
9.2.2 US 108
9.2.2.1 US to dominate North American dental soft-tissue regeneration market 108
9.2.3 CANADA 110
9.2.3.1 Stringent regulatory compliance to support market growth in Canada 110
9.3 EUROPE 112
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 112
9.3.2 GERMANY 115
9.3.2.1 Germany to dominate dental soft-tissue regeneration market in Europe 115
9.3.3 UK 117
9.3.3.1 Rising number of geriatric patients to drive market 117
9.3.4 FRANCE 119
9.3.4.1 Well-established healthcare system to drive market 119
9.3.5 SPAIN 120
9.3.5.1 Government initiatives for providing dental coverage to support market growth 120
9.3.6 ITALY 122
9.3.6.1 Growing penetration of dental products to drive market growth 122
9.3.7 REST OF EUROPE (ROE) 124
9.4 ASIA PACIFIC 125
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 125
9.4.2 JAPAN 128
9.4.2.1 Rising geriatric population to support market growth 128
9.4.3 CHINA 130
9.4.3.1 Growing geriatric population and increasing per capita income to support market growth 130
9.4.4 INDIA 131
9.4.4.1 Growing dental care sector to fuel market growth 131
9.4.5 AUSTRALIA 133
9.4.5.1 Growing healthcare expenditure to aid market growth 133
9.4.6 SOUTH KOREA 135
9.4.6.1 Well-developed healthcare sector to drive market 135
9.4.7 REST OF ASIA PACIFIC 136
9.5 LATIN AMERICA 138
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 138
9.5.2 BRAZIL 140
9.5.2.1 Brazil to hold largest share in Latin American market 140
9.5.3 MEXICO 141
9.5.3.1 Increasing healthcare infrastructure to propel market growth 141
9.5.4 ARGENTINA 143
9.5.4.1 Advancements in dental technology to spur growth 143
9.5.5 REST OF LATIN AMERICA 145
9.6 MIDDLE EAST & AFRICA 146
9.6.1 GOVERNMENT INITIATIVES FOR INFRASTRUCTURAL DEVELOPMENT TO SUPPORT MARKET GROWTH 146
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 146
9.7 GCC COUNTRIES 148
9.7.1 RISING DISPOSABLE INCOMES TO DRIVE MARKET GROWTH 148
9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 148
10 COMPETITIVE LANDSCAPE 150
10.1 OVERVIEW 150
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 150
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DENTAL SOFT-TISSUE REGENERATION MARKET 151
10.3 REVENUE ANALYSIS, 2019–2023 152
10.4 MARKET SHARE ANALYSIS, 2023 152
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 155
10.5.1 STARS 155
10.5.2 EMERGING LEADERS 155
10.5.3 PERVASIVE PLAYERS 155
10.5.4 PARTICIPANTS 155
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 157
10.5.5.1 Company footprint 157
10.5.5.2 Product footprint 158
10.5.5.3 Application footprint 159
10.5.5.4 End-user footprint 160
10.5.5.5 Region footprint 161
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 162
10.6.1 PROGRESSIVE COMPANIES 162
10.6.2 RESPONSIVE COMPANIES 162
10.6.3 DYNAMIC COMPANIES 162
10.6.4 STARTING BLOCKS 162
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 164
10.7 BRAND/PRODUCT COMPARISON 166
10.8 R&D EXPENDITURE OF KEY PLAYERS 167
10.9 COMPANY VALUATION & FINANCIAL METRICS 167
10.10 COMPETITIVE SCENARIO 168
10.10.1 PRODUCT LAUNCHES 168
10.10.2 DEALS 169
10.10.3 EXPANSIONS 171
11 COMPANY PROFILES 172
11.1 KEY PLAYERS 172
11.1.1 GEISTLICH PHARMA AG 172
11.1.1.1 Business overview 172
11.1.1.2 Products offered 172
11.1.1.3 Recent developments 173
11.1.1.3.1 Deals 173
11.1.1.3.2 Expansions 173
11.1.1.4 MnM view 173
11.1.1.4.1 Right to win 173
11.1.1.4.2 Strategic choices 173
11.1.1.4.3 Weaknesses & competitive threats 174
11.1.2 INSTITUT STRAUMANN AG 175
11.1.2.1 Business overview 175
11.1.2.2 Products offered 176
11.1.2.3 MnM view 177
11.1.2.3.1 Right to win 177
11.1.2.3.2 Strategic choices 177
11.1.2.3.3 Weaknesses & competitive threats 177
11.1.3 HENRY SCHEIN, INC. 178
11.1.3.1 Business overview 178
11.1.3.2 Products offered 179
11.1.3.3 Recent developments 180
11.1.3.3.1 Deals 180
11.1.3.4 MnM view 181
11.1.3.4.1 Right to win 181
11.1.3.4.2 Strategic choices 181
11.1.3.4.3 Weaknesses & competitive threats 181
11.1.4 ENVISTA 182
11.1.4.1 Business overview 182
11.1.4.2 Products offered 184
11.1.4.3 Recent developments 184
11.1.4.3.1 Deals 184
11.1.5 ZIMVIE INC. 185
11.1.5.1 Business overview 185
11.1.5.2 Products offered 186
11.1.5.3 Recent developments 187
11.1.5.3.1 Deals 187
11.1.5.4 MnM view 187
11.1.5.4.1 Right to win 187
11.1.5.4.2 Strategic choices 187
11.1.5.4.3 Weaknesses & competitive threats 187
11.1.6 DENTSPLY SIRONA INC. 188
11.1.6.1 Business overview 188
11.1.6.2 Products offered 189
11.1.6.3 Recent developments 190
11.1.6.3.1 Product launches 190
11.1.6.3.2 Deals 190
11.1.6.4 MnM view 190
11.1.6.4.1 Right to win 190
11.1.6.4.2 Strategic choices 190
11.1.6.4.3 Weaknesses & competitive threats 191
11.1.7 ABBVIE INC. 192
11.1.7.1 Business overview 192
11.1.7.2 Products offered 193
11.1.7.3 Recent developments 194
11.1.7.3.1 Expansions 194
11.1.8 ADVANCED MEDICAL SOLUTIONS GROUP PLC 195
11.1.8.1 Business overview 195
11.1.8.2 Products offered 196
11.1.8.3 Recent developments 197
11.1.8.3.1 Deals 197
11.1.9 TISSUE REGENIX 198
11.1.9.1 Business overview 198
11.1.9.2 Products offered 199
11.1.10 SEPTODONT HOLDING 200
11.1.10.1 Business overview 200
11.1.10.2 Products offered 200
11.1.10.3 Recent developments 201
11.1.10.3.1 Deals 201
11.1.11 MEDICAL CONSULT IMPLANTS GMBH 202
11.1.11.1 Business overview 202
11.1.11.2 Products offered 202
11.1.12 MECCELLIS BIOTECH 203
11.1.12.1 Business overview 203
11.1.12.2 Products offered 203
11.1.13 REGEDENT AG 204
11.1.13.1 Business overview 204
11.1.13.2 Products offered 204
11.1.14 REGENITY 205
11.1.14.1 Business overview 205
11.1.14.2 Products offered 205
11.1.14.3 Recent developments 206
11.1.14.3.1 Deals 206
11.1.15 AD SURGICAL 207
11.1.15.1 Business overview 207
11.1.15.2 Products offered 207
11.2 OTHER PLAYERS 208
11.2.1 LIFENET HEALTH 208
11.2.2 B. & B. DENTAL S.R.L. 209
11.2.3 ALPHA-BIO TEC. LTD. 210
11.2.4 LASAK S.R.O. 211
11.2.5 KEYSTONE DENTAL GROUP 212
11.2.6 NEOSS AG 213
11.2.7 BEGO GMBH & CO. KG 214
11.2.8 BIOTECH DENTAL 215
11.2.9 SAMYANG HOLDINGS CORPORATION 216
11.2.10 RTI SURGICAL 217
12 APPENDIX 218
12.1 DISCUSSION GUIDE 218
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 222
12.3 CUSTOMIZATION OPTIONS 224
12.4 RELATED REPORTS 224
12.5 AUTHOR DETAILS 225
❖ 世界の歯科軟組織再生市場に関するよくある質問(FAQ) ❖
・歯科軟組織再生の世界市場規模は？
→MarketsandMarkets社は2024年の歯科軟組織再生の世界市場規模を3.7億米ドルと推定しています。
・歯科軟組織再生の世界市場予測は？
→MarketsandMarkets社は2029年の歯科軟組織再生の世界市場規模を5.4億米ドルと予測しています。
・歯科軟組織再生市場の成長率は？
→MarketsandMarkets社は歯科軟組織再生の世界市場が2024年～2029年に年平均7.8%成長すると予測しています。
・世界の歯科軟組織再生市場における主要企業は？
→MarketsandMarkets社は「Geistlich Pharma AG (Switzerland), Dentsply Sirona (US), Institut Straumann AG (Switzerland), Zimvie Inc. (US), Henry Schein, Inc. (US), AbbVie Inc. (US), Advanced Medical Solutions Group Plc (UK), Tissue Regenix (UK), Septodont Holding (France), Medical Consult Implants GmbH (Germany), Meccellis (US), Regedent Ag (Switzerland), Regenity (US), Envista (US), AD Surgical (US), LifeNet Health (US), B. & B. Dental S.R.L. (Italy), Alpha-Bio Tec. Ltd. (Israel), Lasak S.R.O. (Czechia), KeystoneDentalGroup (US), Neoss AG (Switzerland), Bego GmbH Co. KG (Germany), Biotech Dental (France), Samyang Holdings Corporation (South Korea), and RTI Surgical (US)など ...」をグローバル歯科軟組織再生市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
